CXCR4 and neoplasm: An et al. (2023) developed a novel bispecific glycopeptide (bsGP) that significantly suppresses postoperative recurrence of bladder cancer by simultaneously targeting CD206 on tumor-associated macrophages (TAMs) and CXCR4 on tumor cells, aiming to disrupt the pro-tumorigenic interactions within the TME and prevent tumor relapse after surgery (Figure 7B) [59].